Novartis scraps Phase III ligelizumab trial in peanut allergy

18 Jan 2024

Phase 3

The prospects for Novartis' experimental peanut allergy treatment ligelizumab appear to be crumbling after the company terminated a Phase III trial of the drug, according to an update posted on ClinicalTrials.gov this week. Details about why the study was halted were not specified in the update for the study, which began in 2021 and completed last November.

The next-generation monoclonal anti-IgE antibody remains on the company's pipeline, with food allergy listed as its main indication. The 52-week trial enrolled 211 patients with peanut allergy who were randomised to receive one of two doses of ligelizumab or placebo, delivered by subcutaneous injection once every 4 weeks.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Novartis AG

Indications

Peanut HypersensitivityFood Hypersensitivity

Targets

Drugs

LigelizumabHumanized Anti-IgE monoclonal antibody(Tianchen Biomedical)

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.